STAND. COM. REP. NO. 878

Honolulu, Hawaii

, 2019

RE: H.B. No. 267

H.D. 1

Honorable Scott K. Saiki

Speaker, House of Representatives

Thirtieth State Legislature

Regular Session of 2019

State of Hawaii

Sir:

Your Committee on Consumer Protection & Commerce, to which was referred H.B. No. 267, H.D. 1, entitled:

"A BILL FOR AN ACT RELATING TO PRESCRIPTION DRUGS,"

begs leave to report as follows:

The purpose of this measure is to require drug manufacturers to notify each prescription drug benefit plan and pharmacy benefit manager when there is a proposed increase in the wholesale price of certain drugs that would result in a sixteen percent or greater price increase over a two-year period.

The Hawaii Medical Service Association testified in support of this measure. Pharmaceutical Research and Manufacturers of America and Association for Accessible Medicines testified in opposition to this measure. The Department of Commerce and Consumer Affairs provided comments.

As affirmed by the record of votes of the members of your Committee on Consumer Protection & Commerce that is attached to this report, your Committee is in accord with the intent and purpose of H.B. No. 267, H.D. 1, and recommends that it pass Third Reading.

Respectfully submitted on behalf of the members of the Committee on Consumer Protection & Commerce,

____________________________

ROY M. TAKUMI, Chair